Association of Thrombin-Activatable Fibrinolysis Inhibitor with Acute Pulmonary Embolism

Basit Öğe Kaydı
dc.contributor.authorYıldız, Abdulkerim
dc.contributor.authorKatar, Didem
dc.contributor.authorÖzden Soydaş, Ayşe
dc.contributor.authorAlbayrak, Murat
dc.date.accessioned2021-11-01T15:06:05Z
dc.date.available2021-11-01T15:06:05Z
dc.date.issued2021
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractBackground Thrombin-activatable fibrinolysis inhibitor (TAFI) inhibits fibrinolysis and high levels may have an association with thrombosis. The aim of the current study was to investigate the association of TAFI antigen levels with pulmonary thromboembolism (PTE). Patients and Methods A case-control study was conducted with 29 patients with PTE and 17 age- and gender-matched control individuals. Plasma levels of TAFI were measured at the time of diagnosis, then at 3 and 6 months after the event. Results Initial TAFI levels (%) were higher in patients with PTE than in the control group Initial TAFI levels (%) were higher in patients with PTE than in the control group (190,0 [65,0-250,0] vs 133,0 [83,0-153,0]; p =0.003). TAFI levels significantly decreased at the third and sixth months after initial diagnosis ( p <0.05). The percentage reductions in TAFI levels were 12 and 36.8% at 3 and 6 months, respectively. The Odss ratio (OR) of TAFI level for PTE was found to be 1.024 (95% CI: 1.007-1.040; p =0.005). There was no significant correlation of initial TAFI levels with age, gender, smoking status, history of thrombosis, pulmonary artery pressure, and D-dimer levels ( p >0.05). In the sixth month of treatment, patients with residual thrombosis were seen to have similar baseline levels and reductions of TAFI as patients without residual thrombosis ( p >0.05). Conclusion The result of this study suggests that high TAFI levels may have a role in the occurrence of PTE without impact on treatment outcome.
dc.identifier.citationYıldız, A., Katar, D., Soydaş, A. Ö., & Albayrak, M. (2021). Association of Thrombin-Activatable Fibrinolysis Inhibitor with Acute Pulmonary Embolism. Hämostaseologie.
dc.identifier.doi10.1055/a-1411-7807
dc.identifier.issn0720-9355
dc.identifier.issn2567-5761
dc.identifier.pmid34139773
dc.identifier.scopus2-s2.0-85108817125
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1055/a-1411-7807
dc.identifier.urihttps://hdl.handle.net/11491/7486
dc.identifier.wosWOS:000662651200002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYıldız, Abdulkerim
dc.language.isoen
dc.publisherGeorg Thieme Verlag Kg
dc.relation.ispartofHamostaseologie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTAFIen_US
dc.subjectpulmonary thromboembolismen_US
dc.subjectassociationen_US
dc.titleAssociation of Thrombin-Activatable Fibrinolysis Inhibitor with Acute Pulmonary Embolism
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu